Pediatr Infect Vaccine.  2015 Dec;22(3):206-209. 10.14776/piv.2015.22.3.206.

Intravenous Immunoglobulin Nonresponsive Symptomatic Myocarditis during the Acute Stage of Incomplete Kawasaki Disease

• Sohn Y
• Kim YH

• KMID: 2315687
• DOI: http://doi.org/10.14776/piv.2015.22.3.206

Abstract

We report the case of a 7-year-old boy who showed treatment-nonresponsive hypotension (59/29 mmHg) and decreased left ventricular systolic function (fractional shortening 22%) in the acute stage of Kawasaki disease (KD). The present case serves to highlight that methylprednisolone pulse therapy should be considered in patients with intravenous immunoglobulin nonresponsive symptomatic myocarditis during the acute stage of KD.

Keyword

Kawasaki disease; Corticosteroids; Myocarditis

MeSH Terms

Adrenal Cortex Hormones
Child
Humans
Hypotension
Immunoglobulins*
Male
Methylprednisolone
Mucocutaneous Lymph Node Syndrome*
Myocarditis*
Adrenal Cortex Hormones
Immunoglobulins
Methylprednisolone

Figure

• 

  Fig. 1. Clinical course of the patient. CRP, C-reactive protein; IVIG, intravenous immunoglobulin; MP, methylprednisolone.

• 

  Fig. 2. Change of ejection fraction (%, I), Z score of maximum diameter of right coronary artery (×), and Z score of diameter of left main coronary artery (A) according to the day of admission.

Reference

1. Falcini F, Capannini S, Rigante D. Kawasaki syndrome: an intriguing disease with numerous unsolved dilemmas. Pe—diatr Rheumatol Online I. 2011; 9:17.

2. Newburger JW, Fulton DR. Kawasaki disease. Curr Opin Pediatr. 2004; 16:508— 14.

3. Kim GB, Han JW, Park YW, Song MS, Hong YM, Cha SH, et al. Epidemiologic features of Kawasaki disease in South Korea: data from nationwide survey, 2009—201 1. Pediatr Infect Dis I. 2014; 33:24–7.

4. Kuwabara M, Yashiro M, Kotani K, Tsuboi S, Ae R, Naka—mura Y, et al. Cardiac lesions and initial laboratory data in Kawasaki disease: a nationwide survey in Japan. J Epidemiol. 2015; 25:189–93.

5. Aggarwal P, Suri D, Narula N, Manojkumar R, Singh S. Symptomatic myocarditis in Kawasaki disease. Indian I Pediatr. 2012; 79:813–4.

6. Yoshikawa H, Nomura Y, Masuda K, Hazeki D, Yotsumoto K, Arata M, et al. Four cases of Kawasaki syndrome complicated with myocarditis. Circ I. 2006; 70:202–5.

7. Schultheiss HP, Kuhl U, Cooper LT. The management of myocarditis. Eur Heart]. 2011; 32:2616–25.

8. Rosenfeld EA, Shulman ST, Corydon KE, Mason W, Takahashi M, Kuroda C. Comparative safety and efficacy of two immune globulin products in Kawasaki disease. I Pediatr. 1995; 26:1000–3.

9. Singh S, Rohit M, Gupta A, Suri D, Rawat A. Late sympto—matic myocarditis in Kawasaki disease: an unusual manifes—tation. Indian J Pediatr. 2014; 81:404–5.

10. Saneeymehri S, Baker K, So TY. Overview of pharmacological treatment options for pediatric patients with refractory ka—wasaki disease. I Pediatr Pharmacol Ther. 2015; 20:163–77.

11. Fan PC, Chiu CH, Yen MH, Huang YC, Li CC, Lin TY. School—aged children with Kawasaki disease: high incidence of cervical lymphadenopathy and coronary artery involvement. J Paediatr Child Health. 2003; 39:55–7.